CStone Pharmaceuticals (CSPHF)
OTC Markets OTCPK · USD · Healthcare · Biotechnology
$0.755 (+0.00%) as of
Key statistics
- Market cap
- 1.20B
- EPS (TTM)
- -0.0400
- Dividend yield
- 0.00%
- 52-week range
- 0.5950 – 1.0100
- Beta
- 0.22
- Revenue (TTM)
- 425.23M
- Profit margin
- -98.56%
- Volume
- 2.00k
About CStone Pharmaceuticals
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor, has been approved by the China NMPA for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. It has strategic partnerships with Pfizer, Sanofi, Hengrui, 3SBio Inc., Allist, Ewopharma, Pharmalink, SteinCares, and Gentili. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Suzhou, China
- Employees
- 147
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.